32nd week of 2014 patent applcation highlights part 44 |
Patent application number | Title | Published |
20140219978 | GP100-SPECIFIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein. | 2014-08-07 |
20140219979 | HSP60, HSP60 PEPTIDES AND T CELL VACCINES FOR IMMUNOMODULATION - The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or ameliorating the symptoms of T cell mediated inflammatory and autoimmune disorders, including hepatic disorders, which comprise administering to a subject in need thereof a composition comprising as an active ingredient an effective quantity of a molecule selected from: HSP60, p277, fragments, analogs, homologs and derivatives thereof, and nucleic acids encoding same. Also disclosed are T cell vaccination methods for treating or preventing T cell mediated disorders. | 2014-08-07 |
20140219980 | TREATMENT FOR MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY (MNGIE) - The invention provides a method of treating mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) in a patient, comprising administering to the patient autologous erythrocytes that contain thymidine phosphorylase and are free of animal proteins other than proteins derived from the patient. The erythrocytes generally contain a low amount of endotoxin. | 2014-08-07 |
20140219981 | AMPHIPHILIC PEPTIDES AND HYDROGEL MATRICES THEREOF FOR BONE REPAIR - The present invention relates in general to the field of tissue engineering and more specifically to amphiphilic peptides and peptide matrices thereof useful in vitro and in situ biomineralization and inducing bone repair. The present invention provides peptides, which are useful in hydrogels and other pharmaceutical compositions, and methods and kits of use for bone repair and promotion of biomineralization. Certain hydrogels according to the invention comprise cells within or adhered to the peptide matrix. | 2014-08-07 |
20140219983 | SUPPRESSION OF CANCERS - The present invention relates to a method for suppressing or treating cancer, in particular to a method for suppressing or treating one or more of colorectal cancer, breast cancer, prostate cancer and/or lung cancer. The therapy employs use of a non-cytotoxic protease, which is targeted to a growth hormone-secreting cell such as to a pituitary cell. When so delivered, the protease is internalised and inhibits secretion/transmission of growth hormone from said cell. The present invention also relates to polypeptides and nucleic acids for use in said methods. | 2014-08-07 |
20140219984 | The Use of Alkaline Phosphatase for Preserving Renal Function - The invention relates to the field of medicine and in particular to means and methods for preserving renal function after a treatment with a risk of reducing renal function. The present invention also relates to means and methods for shortening the duration of renal replacement therapy, increasing the creatinine clearance and decreasing the adverse effects of medicaments. | 2014-08-07 |
20140219985 | DISEASE CONTROL WITH TICK PHOSPHOLIPASE A2 - The present invention relates to reagents and methods for the modulation of viability of bacteria. A process is provided wherein a protein sequence from | 2014-08-07 |
20140219986 | DOSING REGIMENS FOR THE TREATMENT OF FABRY DISEASE - The presently disclosed subject matter provides a dosing regimen and administration schedule for the use of 1-deoxygalactonojirimycin and enzyme replacement therapy for the treatment of Fabry disease. The presently disclosed subject matter further provides a dosing regimen and administration schedule for the use of migalastat hydrochloride and agalsidase for the treatment of Fabry disease. | 2014-08-07 |
20140219987 | STABILIZED COMPOSITIONS OF PROTEINS HAVING A FREE THIOL MOIETY - Compositions of proteins having free thiols, and methods of making and using such compositions, are described. | 2014-08-07 |
20140219988 | RRECOMBINANT HUMAN SAPOSIN B PROTEIN CONTAINING PHOSPHORYLATED GLUCOSE RING AND USE THEREOF - The present invention provides a means to ensure a further increase in the therapeutic effects provided by enzyme replacement therapy against lysosomal disease. The present invention is directed to a recombinant human saposin B protein containing phosphorylated carbohydrate chains, a lysosomal enzyme activator comprising such a recombinant protein, and a pharmaceutical composition for treatment of lysosomal disease, which comprises such a recombinant protein and a lysosomal enzyme, etc. | 2014-08-07 |
20140219989 | FACTOR IXA INHIBITORS - The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes. | 2014-08-07 |
20140219990 | WOUND CLEANING CHEMICAL COMPOSITION AND METHOD FOR MANUFACTURING - A wound cleaning chemical composition that includes 2 gs natural salt in 100 mls of water forming a natural salt solution, 50 mgs lactoferrin in 100 mls of water forming a lactoferrin solution, 2 gs sodium bicarbonate in 100 mls of water forming a sodium bicarbonate solution and 1 ml of 95.25% hypochlorite in 100 mls of water forming a hypochlorite solution. The wound cleaning chemical composition also includes a method for manufacturing a wound cleaning chemical composition that includes the steps of preparing an natural salt solution, adding a hypochlorite solution and a sodium bicarbonate solution to the natural salt solution and adding a lactoferrin solution. | 2014-08-07 |
20140219991 | TREATMENT AND COMPOSITION FOR WOUND HEALING - A method and medicament for promoting wound healing in a subject is disclosed. The medicament comprises an effective amount of an agent comprising one or more of;
| 2014-08-07 |
20140219992 | Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof - Provided herein are methods of using modified matrix metalloprotease (MMP) enzymes that exhibit regulated activity in the presence of calcium. The methods include conditionally controlling the activity of the MMPs through the use of calcium to treat fibrotic diseases or conditions involving a component of the extracellular matrix (ECM). | 2014-08-07 |
20140219993 | PLANT VIRUS INFECTION INHIBITOR AND A METHOD FOR INHIBITING PLANT VIRUS INFECTION USING THE SAME - A virus infection inhibitor containing a fermentation by-product such as an amino acid fermentation by-product and a nucleic acid fermentation by-product is sprinkled onto a plant body of a plant, such as tobacco, tomato, bell pepper, and chili pepper to control a disease induced by infection of a virus such as Tobamovirus viruses and Cucumovirus viruses. | 2014-08-07 |
20140219994 | MOLYBDATE-FREE STERILIZING AND PASTEURIZING SOLUTIONS - The present invention concerns a composition and method of using non-molybdate corrosion inhibitors in sterilizing and pasteurizing applications. The composition is a blend of one or more components including corrosion inhibitors, surfactants, hydrotropes, polymer dispersants, pH adjusting agents and water. The composition may include two or more of a) alkyl-dicarboxylic acid; b) phosphono-carboxylic acid; c) tri(amino-carboxylic acid); d) anionic polymer dispersant; e) non-ionic surfactant; f) inorganic phosphate; g) phosphonotricarboxylic acid; and h) hydrotrope. Specifically, the composition may comprise sebacic acid, hydroxyphosphonoacetic acid, and 6,6′,6″-(1,3,5-triazine-2,4,6-triyltriimino)tris-hexanoic acid. Optionally, the composition can further comprise a co-polymer of acrylic acid and allyl-2-hydroxy-propyl-sulfonate ether (AA/AHPSE), 2-phosphono-1,2,4-butane-tricarboxylic acid, sodium phosphate monobasic or phosphoric acid, α-decyl-ω-hydroxy-poly(oxy-1,2ethanediyl), and sodium cumenesulfonate. These components are not necessary, and in some embodiments, the composition is utilized without these components. The disclosed composition exhibits comparable or better corrosion protection performance than conventional molybdate containing sterilizing products. | 2014-08-07 |
20140219995 | INHIBITORS OF BACTERIAL TYPE III SECRETION SYSTEM - Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as | 2014-08-07 |
20140219996 | RUTHENIUM CARBON MONOXIDE RELEASING MOLECULES AND USES THEREOF - The present invention provides novel ruthenium compounds of Formula (I): or salts, isomers, hydrates, or solvates thereof, or combinations thereof; wherein E, R | 2014-08-07 |
20140219997 | Templated Islet Cells and Small Islet Cell Clusters for Diabetes Treatment - A population of small reaggregated islets or clusters engineered from individual islet cells and having improved characteristics as compared to native isolated islets. | 2014-08-07 |
20140219998 | ARMET AS A MARKER FOR CANCER - Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery. | 2014-08-07 |
20140219999 | TREATMENT OF COLON CANCER USING COMPLEMENT INHIBITORS - Methods for treating, preventing or delaying onset of polyp formation and subsequent colon cancer are disclosed. The methods involve administration of a complement inhibitor to inhibit C5a receptor signaling in the tumorigenic or pre-tumorigenic tissue. | 2014-08-07 |
20140220000 | MHC ENGAGEMENT AND CLIP MODULATION FOR THE TREATMENT OF DISEASE - The invention relates to methods for treating disorders by targeting CLIP molecules and MHC. The methods are useful for treating, inhibiting the development of, or otherwise dealing with diseases such as HIV, blood vessel proliferative disorder, cancer and fibrosis. | 2014-08-07 |
20140220001 | Methods and Monitoring of Treatment with a DLL4 Antagonist - Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity. | 2014-08-07 |
20140220002 | COMBINATION THERAPIES EMPLOYING GITR BINDING MOLECULES - The present invention provides combination therapies that employ a GITR binding molecule in combination with one or more additional agents. | 2014-08-07 |
20140220003 | THERAPEUTIC METHOD FOR MESOTHELIOMA - The present invention relates to a therapeutic method and a diagnostic method using an antibody that binds to a ganglioside GM2 antigen, and a therapeutic agent and a diagnostic agent comprising as an active ingredient an antibody that binds to a ganglioside GM2 antigen. According to the present invention, the prognosis of GM2 positive mesothelioma patients can be improved by diagnosing and treating GM2 positive mesothelioma patients with a diagnostic agent and a therapeutic agent that comprise an anti-ganglioside GM2 antibody as an active ingredient. | 2014-08-07 |
20140220004 | COMPOSITIONS AND METHODS FOR TREATING PAIN - Provided herein are compositions containing an antibody or antigen-binding antibody fragment that specifically binds to metallothionein 2 (MT2) protein, and compositions containing an agent that binds to or neutralizes a function of MT2 protein and/or an oligonucleotide that decreases the expression of MT2 mRNA in a mammalian cell, and optionally, one or more anti-inflammatory agents and/or analgesics. Also provided are methods of decreasing pain in a mammal that include administering to the mammal an agent that binds to or neutralizes a function of MT2 protein and/or an oligonucleotide that decreases the expression of MT2 mRNA in a mammalian cell, in an amount sufficient to decrease the level of extracellular MT2 protein or neutralize a function of extracellular MT2 protein in the mammal, thereby decreasing pain in the mammal. | 2014-08-07 |
20140220005 | N-Cadherin: Target for Cancer Diagnosis and Therapy - The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that express N-cadherin, including prostrate and bladder cancers. | 2014-08-07 |
20140220006 | LUNG CANCER BIOMARKERS - The present invention relates to methods of diagnosing lung cancer in a patient, as well as methods of monitoring the progression of lung cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein. | 2014-08-07 |
20140220007 | LUPUS BIOMARKERS - The present invention relates to methods of diagnosing lupus in a patient, as well as methods of monitoring the progression of lupus and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein. | 2014-08-07 |
20140220008 | Humanized Anti-CD4 Antibody With Immunosuppressive Properties - A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions. | 2014-08-07 |
20140220009 | Compositions and Methods for Treating Cocaine-Related Disorders - A method of treating a cocaine-related disorder in an individual is provided, the method including administering to the individual a therapeutic amount of an antibody comprising a human immunoglobulin gamma heavy chain and a murine lambda light chain. In a specific embodiment, the antibody is a monoclonal antibody comprising a murine lambda light chain variable region, a human gamma heavy chain variable region, and a human kappa or lambda light chain constant region. | 2014-08-07 |
20140220010 | VARIANTS OF HUMANIZED IMMUNOMODULATORY MONOCLONAL ANTIBODIES - The present invention relates to humanized monoclonal antibodies, pharmaceutical compositions that include the same, and use thereof for the treatment of a variety of indications, particularly cancer and immunodeficiency disorders. In particular, the present invention provides modified antibodies or fragments thereof having specific amino acid modifications compared to the humanized monoclonal immunomodulatory antibody termed hBAT-1. | 2014-08-07 |
20140220011 | POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS - This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, ClORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and ClORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development. | 2014-08-07 |
20140220012 | Novel VISTA-Ig constructs and the use of VISTA-Ig for Treatment of Autoimmune, Allergic and Inflammatory Disorders - The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig), preferably also containing a flexible linker intervening the VISTA and Ig Fc polypeptide. The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions, especially lupus, multiple sclerosis, psoriasis, psoriatic arthritis, multiple sclerosis, Crohn's disease, inflammatory bowel disease and type 1 or type 2 diabetes. | 2014-08-07 |
20140220013 | METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF MALIGNANT DISEASES - Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin. | 2014-08-07 |
20140220014 | LEVELS OF BCMA PROTEIN EXPRESSION ON B CELLS AND USE IN DIAGNOSTIC METHODS - The present invention provides a method of measuring the levels of BCMA in a biological sample, specifically upon the B cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE, and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with BLyS antagonists, either singly or in combination with other immune suppressive drugs | 2014-08-07 |
20140220015 | COMBINATIONS OF MODALITIES FOR THE TREATMENT OF DIABETES - A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a T-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a Type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule and a Type 1 diabetes autoantigen. Pharmaceutical compositions are also provided herewith. | 2014-08-07 |
20140220016 | ANTIBODY- ENDOSTATIN FUSION PROTEIN AND ITS VARIANTS - Methods of inhibiting the growth of tumors comprising administering chimeric fusion molecules comprising endostatin mutants and all or a portion of anti-Her2 or anti-EGFR antibodies. | 2014-08-07 |
20140220017 | SERUM HALF-LIFE EXTENSION USING IGBD - The present invention relates to complexes comprising (i) an immunoglobulin (Ig) binding moiety and (ii) a pharmaceutically active moiety, wherein the Ig binding moiety specifically binds to the constant domain 1 of the heavy chain (C | 2014-08-07 |
20140220018 | BIOMARKERS FOR EPITHELIAL CANCER DIAGNOSIS AND TREATMENT - Disclosed herein are methods for diagnosing the state of an epithelial tumor or tissue in a subject. Also disclosed are methods of diagnosing tumor initiation in an epithelial tissue of a subject. Also disclosed are methods of determining prognosis of a subject with an epithelial tumor. These methods include, in part, measuring the amount of pSer239-VASP, pSer157-VASP, and/or total VASP in a subject or in a tissue or tumor of a subject and comparing those levels to an appropriate reference level. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2014-08-07 |
20140220019 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided. | 2014-08-07 |
20140220020 | IL-1 BINDING PROTEINS - Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions. | 2014-08-07 |
20140220021 | THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES COMPRISING PD-1 AGONIST - Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a PD-1 agonist as an active ingredient and is administered (a) 1 to 10 times within one month from the first administration, (b) in a total PD-1 agonist dose of 20 to 1250 μg/kg, and (c) without requiring administration for at least 3 months after the last administration. | 2014-08-07 |
20140220022 | PTHRP, ITS ISOFORMS AND ANTAGONIST THERETO IN THE DIAGNOSIS AND TREATMENT OF DISEASE - The present invention is directed to the diagnosis and treatment of diseases, preferably the inhibition of tumor growth and its progression to metastatic sites, through the inhibition of the production of PTHrP, its isoforms or PTHrP signalling. The present invention is also directed to methods of inhibiting the PTHrP1-173 isoform through antagonists thereof, including monoclonal antibodies and siRNA directed there against. The invention may be applicable to many disease states, including but not limited to several types of cancer (such as breast, lung, prostate, melanoma and squamous) expressing PTHrP and its isoforms, alone or in combination with other therapeutic agents. | 2014-08-07 |
20140220023 | METHOD OF TREATING OSTEOARTHRITIS WITH AN ANTIBODY TO NGF - Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved. | 2014-08-07 |
20140220024 | CHYMASE COMPOSITIONS, ANTIBODIES, DIAGNOSTICS, AND THERAPEUTIC METHODS RELATED THERETO - The disclosure relates to chymase, antibodies to chymase, and diagnostic and therapeutic methods relates thereto. It has been discovered that above certain circulating levels of chymase, a patient has a high likelihood of AVF nonmaturation. Compositions and methods of detecting and measuring chymase levels are disclosure herein. In certain embodiments, the disclosure relates to methods of determining the effectiveness of creating an arteriovenous fistula in a subject diagnosed with chronic kidney disease. | 2014-08-07 |
20140220025 | NOVEL STIP1 POLYPEPTIDES AND USES THEREOF - The present invention is directed toward pharmaceutical compositions comprising an isolated polypeptide and a pharmaceutically acceptable carrier. The present invention also discloses an antibody or an antigen-binding portion thereof that bind to the isolated polypeptide. Methods of inhibiting cancer cells growth are also disclosed, comprising administering the isolated polypeptide or the antibody described herein to a subject in need thereof. | 2014-08-07 |
20140220026 | THERAPEUTIC USE OF SPECIFIC LIGAND IN MSRV ASSOCIATED DISEASES - A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6. | 2014-08-07 |
20140220027 | 1D05 PCSK9 ANTAGONISTS - Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure. | 2014-08-07 |
20140220028 | ANTIBODIES DIRECTED AGAINST SIGNAL PEPTIDES, METHODS AND USES THEREOF - Provided are methods employing antibodies directed against the signal peptide (SP) domain of various disease-associated polypeptides. These anti-SP antibodies detect cell surface expression of these SP domains and are used in methods of diagnosis and/or therapy. Provided is a method for determining the suitability for treatment of a subject suffering from a disease, whereby detection of cell surface expression of a specific SP indicates that the subject would benefit from therapy directed against this SP. Further, provided are methods for diagnosis of diseases based on the detection of endogenously produced anti-SP antibodies. | 2014-08-07 |
20140220029 | COMBINED USE OF A MODULATOR OF CD3 AND A GLP-1 COMPOUND - Methods and uses for the prevention and intervention of Type 1 diabetes comprising administration of a modulator of CD3 and a GLP-1 compound. | 2014-08-07 |
20140220030 | USE OF CGRP ANTAGONIST COMPOUNDS FOR TREATMENT OF PSORIASIS - The invention provides methods and compositions for treating, preventing and/or remedying psoriasis, based on compounds that have a calcitonin-related gene peptide (CGRP) antagonistic effect. Methods are also disclosed for identifying compounds with CGRP antagonist activity which thereby are suitable candidate compounds for treating psoriasis. | 2014-08-07 |
20140220031 | ANTI-CD154 ANTIBODIES - The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject. | 2014-08-07 |
20140220032 | DDR2 MUTATIONS AS TARGETABLE FEATURES OF MELANOMA OR BASAL CELL CARCINOMA - Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF. | 2014-08-07 |
20140220033 | Administration of an Anti-Activin-A Compound to a Subject - The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment by evaluating the subject's expression levels of specific biomarkers or angiogenic factors. | 2014-08-07 |
20140220034 | Serpinf2-Binding Molecules and Method of Use Thereof - Compositions and methods of using SerpinF2-binding molecules for preventing and/or reducing organ damage, functional disability or mortality in a patient at risk due to the activity of SerpinF2 and/or plasminogen activators on tissue injury. Also provided are compositions and methods of using SerpinF2-binding molecules for inhibiting hemorrhage, edema, and apoptosis. Methods for the preparation of medicaments for such methods of treatment and prevention are provided. | 2014-08-07 |
20140220035 | METHOD FOR DETECTING NOVEL FGFR4 MUTANT - [Problem] An object of the present invention is to elucidate a novel genetic mutation which is a cause of cancer, and thereby, to provide a method for detecting the genetic mutation, or a protein which has the mutation, a method for detecting the presence of cancer in a subject, a method for diagnosing cancer in a subject, and a primer set, a probe and a detecting kit for the methods. | 2014-08-07 |
20140220036 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND FOR IDENTIFYING AGENTS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES - The present invention provides methods of inhibiting a tau protein such as h-tau | 2014-08-07 |
20140220037 | METHODS FOR TREATING REPERFUSION INJURIES - The present invention relates to treating a tissue in a mammal from the effects of reperfusion using flagellin | 2014-08-07 |
20140220038 | LRP1 AS KEY RECEPTOR FOR THE TRANSFER OF STERIFIED CHOLESTEROL FROM VERY-LOW-DENSITY LIPOPROTEINS (VLDL) TO ISCHAEMIC CARDIAC MUSCLE - The invention relates to novel molecules that can modulate one of the mechanisms leading to the massive deposition of cholesterol in the cardiomyocytes and/or in the smooth muscle cells of the vascular wall, during acute myocardial infarction or other clinical situations involving ischaemia. The invention also shows that the blockage of LRP1 by means of certain agents, including a recombinant expression vector, an RNAi, an antibody, a siRNA etc., prevents the overaccumulation of esterified cholesterol in the cardiomyocytes and/or in the smooth muscle cells of the vascular wall exposed to ischaemia. The invention also relates to the use of said molecules in the treatment and/or prevention of the changes in the metabolism of calcium and cardiac remodeling associated with ischaemia. | 2014-08-07 |
20140220039 | ApoIII and the Treatment and Diagnosis of Diabetes - The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes comprising contacting pancreatic β cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in the pancreatic β cells. The present invention also provides methods for treating patients with type I diabetes comprising administering to the patient an amount effective of an inhibitor of apoCIII to reduce apoCIII-induced increase in intracellular calcium concentration in pancreatic β cells. | 2014-08-07 |
20140220040 | ANTIBODIES TO LRP6 - Anti-LRP6 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. These anti-LRP6 antibodies can be used to enhance Wnt activity and/or antagonize Dkk1 activity. Also described are methods of therapy using such antibodies and antigen-binding regions to bind modulate Wnt/LRP6 signaling to promote tissue homeostasis, regeneration and repair in diseases such as, but not limited to, bone disorders, such as osteoporosis, rheumatoid arthritis, and osteolytic lesions caused by osteoarthritis and multiple myeloma, gastrointestinal disease and wound healing. | 2014-08-07 |
20140220041 | COMPOUNDS FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE - The invention relates to a method of modulating concentration of Alzheimer's Disease (AD) relevant proteins amyloid precursor protein (APP), beta (β) and gamma (γ) secretases and amyloid beta peptide (Aβ), and also relates to a method of reducing Aβ shedding. Furthermore, this invention extends to a compound for use in the treatment of AD, and also to a method of treating AD. | 2014-08-07 |
20140220042 | ANTI-C (EPSILON)MX ANTIBODIES CAPABLE OF BINDING TO HUMAN MIGE ON B LYMPHOCYTES - The invention pertains to the generation and utility of antibodies that can bind effectively to CεmX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The CεmX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP (SEQ ID NO:1) peptide at the C-terminal of CεmX, have now been found to bind poorly to mIgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL (SEQ ID NO:2) and HSGQQQGLPRAAGGSVPHPR (SEQ ID NO:3), of CεmX can bind effectively to mIgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE. | 2014-08-07 |
20140220043 | GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS - Disclosed herein is a driver gene signature for predicting survival in patients with solid tumors, such as hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten tumor-associated genes, SH2D4A, CCDC25, ELP3, DLC1, PROSC, SORBS3, HNRPD, PAQR3, PHF17 and DCK. A decrease in DNA copy number or mRNA expression of SH2D4A, CCDC25, ELP3, DLC1, PROSC and SORBS3 in solid tumors is associated with a poor prognosis, while a decrease in DNA copy number or mRNA expression of HNRPD, PAQR3, PHF17 and DCK in solid tumors is associated with a good prognosis. Methods of predicting the prognosis of a patient diagnosed with HCC or breast cancer by detecting expression of one of more tumor-associated genes, and methods of treating a patient diagnosed with HCC or breast cancer by administering an agent that alters expression or activity of one or more of the disclosed tumor-associated genes, are described. | 2014-08-07 |
20140220044 | METHOD FOR THE PRODUCTION OF HYDROLYZED ALLERGENS - A method for the production of hydrolyzed allergens from allergens comprising the steps of:
| 2014-08-07 |
20140220045 | Compositions of a Peptide Targeting System for Treating Cancer - This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells. | 2014-08-07 |
20140220046 | Sialic Acid Derivatives For Protein Derivatisation And Conjugation - Derivatives are synthesised of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. The derivatives may be reacted with substrates, for instance containing amine or hydrazine groups, to form non-cross-linked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs peptides or proteins or drug delivery systems. | 2014-08-07 |
20140220047 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 2014-08-07 |
20140220048 | APOPTOTIC CELL-MEDIATED TRANSFECTION OF MAMMALIAN CELLS WITH INTERFERING RNA - Mammalian host cells for use in a cell-mediated tranfection process, which contain an RNAi molecule and an expression vector for a pro-apoptotic protein. The method includes inducing apoptotic cell (AC) death in mammalian cells that contain an RNAi molecule capable of downregulating a chosen target gene. Living cells expressing the target gene are then exposed to the ACs. The ACs are processed by the living cells, and the RNAi molecule in the ACs downregulates the expression of the target gene in living cells. | 2014-08-07 |
20140220049 | MICRORNA INHIBITION FOR THE TREATMENT OF INFLAMMATION AND MYELOPROLIFERATIVE DISORDERS - The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arntl, Picalm, Jarid2, PU.1, Csflr, HIFlα, Sla, Cepbβ, and Bach1, and the like. | 2014-08-07 |
20140220050 | NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS - The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect. | 2014-08-07 |
20140220051 | METHODS OF MODULATING HVEM, BTLA AND CD160 CIS COMPLEX RESPONSE OR SIGNALING ACTIVITY WITH SOLUBLE LIGHT POLYPEPTIDE SEQUENCES - The invention provides HVEM cis complexes which include, for example, HVEM/BTLA, HVEM/CD160 and HVEM/gD cis complexes. The invention provides ligands and agents that bind to HVEM cis complexes, such as antibodies. The invention further provides methods of use of the HVEM cis complexes, and the ligands and agents (e.g., LIGHT polypeptide sequence) that bind to the HVEM cis complexes. | 2014-08-07 |
20140220052 | COMPOSITIONS AND METHODS FOR WOUND HEALING, AND FOR RECRUITMENT AND ACTIVATION OF MACROPHAGES IN INJURED TISSUES AND IN IMPLANTED BIOMATERIALS USED FOR TISSUE ENGINEERING - The present invention is related to the field of wound healing or tissue regeneration due to disease (i.e., for example, cardiovascular diseases, osetoarthritic diseases, or diabetes) and to healing of internal injuries. In particular, the present invention provides compositions and methods comprising molecules and nanoparticles with linked α-gal epitopes for induction of recruitment and activation of macrophages localized within or surrounding damaged and/or injured tissue. The recruited macrophages further recruit stem cells into the injured tissues. The recruited macrophages and stem cells promote the repair and regeneration of the treated injured tissue. In some embodiments, the present invention provides treatments for tissue repair in normal subjects and in subjects having impaired healing capabilities, such as diabetic and aged subjects. In some embodiments, the present invention provides treatments for injured tissues such as brain, peripheral nerve, heart muscle, skeletal muscle, lung, cartilage, bone, gastrointestinal tract and dysfunctional endocrine tissues. The invention further provides methods and compositions comprising molecules and nanoparticles with linked α-gal epitopes for inducing recruitment and activation of macrophages into biomaterial implants for improving the conversion of such implants into functional tissues and organs within treated patients. | 2014-08-07 |
20140220053 | MICROVESICLES ISOLATED FROM MESENCHYMAL STEM CELLS FOR USE AS IMMUNOSUPPRESSIVE AGENTS - The present invention concerns microvesicles isolated from mesenchymal stem cells as immunosuppressive agents for treatment of inflammatory and immune pathologies. | 2014-08-07 |
20140220054 | WT1 HLA CLASS II-BINDING PEPTIDES AND COMPOSITIONS AND METHODS COMPRISING SAME - This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same. | 2014-08-07 |
20140220055 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION - The present invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject. | 2014-08-07 |
20140220056 | VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION - Disclosed is a vaccine composition for transdermal administration to induce cellular immunity, comprising an antigen, wherein Th1 cell ratio in a model animal for immunological evaluation that received the composition is 10% or more. | 2014-08-07 |
20140220057 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION - The present invention provides a cancer vaccine composition for transdermal administration for cellular immunity induction, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a pharmacologically acceptable acid as a first cellular immunity induction promoter, or a pharmacologically acceptable salt thereof. | 2014-08-07 |
20140220058 | VACCINE COMPOSITION FOR TRANSDERMAL OR MUCOSAL ADMINISTRATION - The invention provides a vaccine composition for transdermal or transmucosal administration for inducing cellular immunity, comprising (i) an antigen; and (ii) a pharmacologically acceptable acid or a pharmacologically acceptable salt thereof as a first cellular immunity induction promoter. | 2014-08-07 |
20140220059 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION - The present invention provides a cancer vaccine composition for mucosal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject. | 2014-08-07 |
20140220060 | HIV-1 SOUTH AFRICAN SUBTYPE C ENV PROTEINS - The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof. | 2014-08-07 |
20140220061 | YEAST EXPRESSION OF FLAVIVIRUS VIRUS-LIKE PARTICLES AND USE THEREOF - Described herein is a method for the production of flavivirus virus-like particles (VLPs) in a yeast system. In some cases, flavivirus structural proteins are expressed in a | 2014-08-07 |
20140220062 | CONDITIONAL REPLICATING CYTOMEGALOVIRUS AS A VACCINE FOR CMV - The present invention relates to methods of inducing an immune response to cytomegalovirus (CMV) using a genetically modified CMV that is conditionally replication defective. The methods of the invention can be used to treat and/or prevent primary CMV infection, infection due to reactivation of a latent CMV and a super-infection of a different strain of CMV that had been previously encountered. The present invention also relates to a replication defective CMV which has been recombinantly altered to allow for external control of viral replication. Compositions comprising the replication defective CMV are also encompassed by the present invention. | 2014-08-07 |
20140220063 | VACCINE COMPOSITION - The invention provides a vaccine composition containing an antigen for inducing cellular immunity, comprising at least one first cellular immunity induction promoter. | 2014-08-07 |
20140220064 | IMMUNIZING COMPOSITION - The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of | 2014-08-07 |
20140220065 | THERAPEUTIC APPLICATION OF S. PYOGENES C-TERMINAL PEPTIDE - A method for treating rheumatic heart disease comprising administering an immunogenic composition against group A beta hemolytic streptococcus | 2014-08-07 |
20140220066 | GROUP A STREPTOCOCCUS MULTIVALENT VACCINE - Immunogenic compositions are provided herein that are useful for inducing an immune response specific against group A | 2014-08-07 |
20140220067 | LIVE ATTENUATED CHIMERIC PORCINE CIRCOVIRUS VACCINE - The present invention provides a novel chimeric porcine circovirus infectious DNA clone and live attenuated chimeric virus with the PCV2, preferably of subtype PCV2b, capsid gene integrated into a non-pathogenic PCV1 virus genome. In a particular embodiment, the PCV2 capids gene is of subtype PCV2b, the predominant subtype circulating in pigs worldwide. The attenuated chimeric virus, designated PCV1-2b, effectively protects pigs from PCV2b challenges, and can be used as a live vaccine, as well as an inactivated (killed) vaccine, that provides protection and cross protection against PCV2b and PCV2a subtypes infection. The live attenuated vaccine of the present invention is also effective protecting pigs from porcine circovirus-associated disease (PCVAD). | 2014-08-07 |
20140220068 | NOVEL XYLOGONE GANODERMOPHTHORA STRAIN WITH ANTIFUNGAL ACTIVITY, AND COMPOSITION INCLUDING SAME FOR PREVENTING PLANT DISEASES - A novel ascomycetous | 2014-08-07 |
20140220069 | ACTIVE INGREDIENT DERIVED FROM TORULASPORA DELBRUECKII AND COSMETIC USE FOR IMPROVING AND/OR REPAIRING THE BARRIER FUNCTION OF THE SKIN - An active ingredient derived from | 2014-08-07 |
20140220070 | USE OF PLANT CELL MEMBRANE TREATMENT OF OBESITY - The present invention relates to the use of a composition comprising at least one cell membrane fraction or parts thereof, for the reduction of lipolytic activity and/or to retard fat digestion, suppress appetite, body weight and/or lower blood lipids. The invention also relates to the use of said hydrophobic peptide in a pharmaceutical as well as a food composition and methods of treating a mammal with said composition. | 2014-08-07 |
20140220071 | BIOLOGICALLY ACTIVE FOOD ADDITIVE FOR NORMALIZING THE FUNCTION OF THE THYROID GLAND - An active biologically active dietary additive for the normalization of the thyroid gland function contains roots, rhizomes or the herb of white cinquefoil, or their mixture, | 2014-08-07 |
20140220072 | SHIGELLA-DERIVED VECTOR AND METHODS OF USING THE SAME - Recombinant vectors comprising the cell entry region of the | 2014-08-07 |
20140220073 | Immunization Compositions and Methods - The present invention provides methods and compositions to induce neutralizing antibodies in mammals to serotypes of dengue virus, measles virus, mumps virus, rubella and/or VZV virus. | 2014-08-07 |
20140220074 | Toll-Like Receptor 4 (Tlr-4) Agonist Peptides For Modulating Tlr-4 Mediated Immune Response - Peptides including an amino acid sequence of a fragment of mammalian Toll-like receptor-4 (TLR-4), analogs and derivatives thereof, and pharmaceutical compositions including these peptides. Methods for modulating a TLR-4 mediated immune response, particularly stimulating TLR-4 mediated immune response, thereby treating infectious diseases and cancer. | 2014-08-07 |
20140220075 | MULTI PLASMID SYSTEM FOR THE PRODUCTION OF INFLUENZA VIRUS - Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. | 2014-08-07 |
20140220076 | Recombinant Mistletoe Lectin and use Thereof as an Adjuvant - The invention relates to vaccines that comprise antigens and an adjuvant, and to the use of the adjuvant, wherein the adjuvant is selected from a recombinant mistletoe lectin. | 2014-08-07 |
20140220077 | New Modified Live Flavobacterium Strains, Stabilized Vaccines Comprising Same, and Methods of Making and Use Thereof - The present invention provides attenuated | 2014-08-07 |
20140220078 | Method for Preparing Glucans Based on Aspergillus niger - This application concerns a method for preparing glucan from | 2014-08-07 |